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 41 
Highlights 42 
• Proteomic analysis of synapses isolated from Alzheimer’s disease and control subject 43 
brains identifies over 5,500 proteins in human synapses. 44 
• In silico analysis reveals region-specific decreases in proteins involved in synaptic 45 
and mitochondrial function and increases in proteins involved in neuroimmune 46 
signaling and intracellular signaling in AD. 47 
• The apolipoprotein E4 risk gene is associated with exacerbated changes in synaptic 48 
proteins in AD. 49 
 50 
Abstract 51 
Degeneration of synapses in Alzheimer’s disease (AD) strongly correlates with cognitive 52 
decline, and synaptic pathology contributes to disease pathophysiology. We recently 53 
discovered that the strongest genetic risk factor for sporadic AD, apolipoprotein E epsilon 4 54 
(APOE4), exacerbates synapse loss and synaptic accumulation of oligomeric amyloid beta in 55 
human AD brain.  To begin to understand the molecular cascades involved in synapse loss in 56 
AD and how this is mediated by APOE, and to generate a resource of knowledge of changes 57 
in the synaptic proteome in AD, we conducted a proteomic screen and systematic in-silico 58 
analysis of synaptoneurosome preparations from temporal and occipital cortices of human 59 
AD and control subjects with known APOE gene status.  Our analysis identified over 5,500 60 
proteins in human synaptoneurosomes and highlighted disease, brain region, and APOE-61 
associated changes in multiple molecular pathways including a decreased abundance in AD 62 
of proteins important for synaptic and mitochondrial function and an increased abundance of 63 
proteins involved in neuroimmune interactions and intracellular signaling. 64 
 65 
Introduction 66 
Dementia poses one of the biggest societal challenges of the 21st century. Over 50 million 67 
people are living with dementia worldwide, it costs over $800 billion per year to care for 68 
them, and there are currently no disease modifying treatments 1.  One of the barriers to 69 
developing effective therapies for Alzheimer’s disease, the most common cause of dementia, 70 
lies in the lack of a comprehensive understanding of the brain changes that cause 71 
neurodegeneration. Extracellular amyloid beta (Aβ) plaques, intracellular neurofibrillary 72 
tangles composed of hyperphosphorylated tau protein, and severe brain atrophy are the major 73 
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neuropathological hallmarks of AD 2. There are many genetic risk factors for developing 74 
sporadic AD, the strongest of which is inheritance of the apolipoprotein E epsilon 4 allele 75 
(APOE4).  Inheritance of one copy of APOE4 is associated with a 3 fold increase in disease 76 
risk and inheritance of two copies with an over 10 fold increased risk 3.  In addition to its 77 
known roles in Aβ production and clearance, we have observed that apoE protein is involved 78 
in Aβ-mediated synapse degeneration 4, 5, which is important as synapse loss is  the strongest 79 
pathological correlate with cognitive decline in AD 6, 7, 8. ApoE4 causes more synaptic loss 80 
around plaques when expressed in mouse models of familial AD 4. Using high resolution 81 
imaging in human post-mortem brain tissue, we similarly observed exacerbated synapse loss 82 
in APOE4 carriers and further that apoE4 is associated with more accumulation of oligomeric 83 
Aß at synapses 5.  More recent data implicates APOE4 in tau mediated neurodegeneration 9 84 
and also inflammatory TREM2 mediated microglial phenotypes 10, which may be important 85 
for synapse degeneration. 86 
 87 
Recent data from postnatal human brain samples shows that proteomic datasets can reveal 88 
differences in proteins that are not observed in RNA expression data, arguing the importance 89 
of building strong resource datasets at the level of protein in human diseases 11. Thus far there 90 
have been several proteomic studies of human AD brain tissue (supplemental table 1), but a 91 
comprehensive dataset on human synaptic proteins examining the downstream molecular 92 
effects of APOE genotype in AD remains unavailable.  93 
 94 
In order to further our understanding of how APOE may be influencing synaptic vulnerability 95 
in AD, we have performed a comprehensive proteomic study of human post-mortem brain 96 
tissue through a series of molecular comparisons allowing us to assess the relative 97 
contribution of both regional vulnerability and APOE variants to AD pathogenesis. Although 98 
our study is in postmortem tissue which has inherent limitations including looking at a 99 
snapshot of the end stage of the disease, the inclusion of a less affected brain region allows 100 
some novel insight into changes that may be occurring in synapses earlier in the degenerative 101 
process. We provide a unique proteomic resource identifying over 5,500 proteins in human 102 
synaptoneurosome preparations. Additionally, we highlight multiple proteins and molecular 103 
pathways that are modified in AD with brain region and APOE genotype status.  In silico 104 
analysis reveals that proteins involved in glutamatergic synaptic signalling and synaptic 105 
plasticity are decreased in AD with temporal cortex (which has high levels of pathology) 106 
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being more severely affected than occipital cortex (which has lower levels of pathology) and 107 
APOE4 carriers more affected than APOE3 carriers.  Alterations in glial proteins important 108 
for neuroimmune signalling were also detected using in silico analysis, and further 109 
investigation revealed a host of proteins involved in the complement cascade are not only 110 
found in human synapses but are increased in AD compared to control brain.  In addition to 111 
providing a resource for the field, our data support the hypothesis that APOE genotype plays 112 
an important role in synaptic dysfunction and degeneration in AD.   The proteins and 113 
pathways identified as altered in this study can now be investigated in more detail for their 114 
potential targeted therapies to delay or prevent synaptic alterations and the consequential 115 
symptoms contributing to dementia. 116 
 117 
Results 118 
Development of a human post-mortem synaptic reference proteome 119 
To better understand the changes in synapses that may contribute to disease pathogenesis in 120 
AD and how the genetic risk factor APOE contributes to synaptic vulnerability, we conducted 121 
a comprehensive proteomic study of human post-mortem brain tissue.  For this study, we 122 
examined two brain regions, superior temporal gyrus (BA41/42) which has a severe 123 
pathological burden and primary visual cortex (BA17) which is less severely affected even at 124 
the end stages of disease (Figure 1A & B 2). With this study design incorporating disease, 125 
brain region, and APOE genotype, it is possible to design a series of comparisons which will 126 
enable the interrogation of complex proteomic comparisons in a biologically meaningful way 127 
(Figure 1C). Through the MRC Edinburgh sudden death brain bank, we were able to access 128 
samples from 34 brain tissue donors whose condition and underlying genetics were amenable 129 
to this particular investigation. Details of subjects in the study can be found in Table 1.  130 
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 131 
 132 
Fig. 1: Increased pathology in temporal compared to occipital cortex and in APOE4 133 
compared to APOE3 carriers.  Representative images of immunohistochemistry for 134 
amyloid beta (A) and tau (B) highlight the higher pathological load in APOE4 carriers than 135 
APOE3 carriers and more pathology in superior temporal gyrus (BA41/42) compared to 136 
primary visual cortex (BA17). For analysis, we examined ratios of AD vs control samples in 137 
the 2 brain regions and with APOE3/3 or APOE3/4 genotype to examine how the synaptic 138 
proteome changes with differential pathology (C). Scale bars represent 200µm (A) 50µm (B). 139 
 140 
Synaptic preparations were prepared and quality control for post-mortem protein degradation 141 
were confirmed as previously described12, 13, 14 (Supplementary Figure 1 for example total 142 
protein stains and western blotting).  Any synaptoneurosome preparations containing nuclear 143 
histone protein were discarded and fresh preparations made from the same case.  Protein 144 
degradation was assessed using the “HUSPIR” ratio or degradation index 15. To find this 145 
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value, synaptoneurosmes run on western blot were probed using an antibody against 146 
NMDAR2B which recognizes two bands, the full-length protein at 170 kDa and a 147 
degradation product at 150kDa. This degradation only occurs post-mortem as it is not found 148 
in biopsy tissue thus comparing these two bands is an accepted indication of post mortem 149 
synaptic protein degradation. The degradation index was found to significantly correlate with 150 
RNA integrity number (p=0.009, R2=0.215, linear regression analysis) and lower but still 151 
significant correlation with brain pH (p=0.023, R2=0.184, linear regression analysis) but not 152 
at all with Post Mortem Interval.  RIN and pH are routinely collected for all brain bank 153 
samples and used as a proxy for tissue integrity. Here we confirm that protein degradation 154 
correlates better with these markers than with post-mortem interval highlighting the 155 
importance of tissue handling in maintaining protein integrity. 156 
157 
Table 1: Subject characteristics. 158 
 159 
Having confirmed that the extracted protein is of appropriate quality, we then applied a 160 
comprehensive workflow to enable us to assess (at the protein level) the relative contribution 161 
of both regional vulnerability and APOE variants as a risk factors to AD pathogenesis (Figure 162 
1C, Figure 2) 12, 13. We performed a complex 8-plex TMT LC-MS/MS analysis. 163 
Representative pools based on the outlined groupings were generated from these synaptic 164 
protein extracts. By pooling individual samples according to APOE genotype and cortical 165 
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area, we were able to reduce potential noise in the system generated through inter individual 166 
differences, subtle post mortem handling differences and/or sample isolation 16. Thus, 25 μg 167 
of each of the 34 subjects were pooled according to disease status, APOE genotype (3/3 or 168 
3/4) and brain region (BA41/42 or BA17). The inclusion of an equivalent proportion of each 169 
protein isolate into a readily comparable pool allowed the generation of a molecular 170 
fingerprint representative of each condition and enables subsequent analysis of individual 171 
patient variability in the resulting validatory work (as a deviation from the population signal, 172 
as previously described 14, 17).   173 
 174 
 175 
Supplemental Figure 1: Enrichment and integrity analysis of synaptic proteins. A) A 176 
representative western blot from 3 cases shows the enrichment of synaptic proteins and 177 
exclusions of histones from the synaptoneurosome preparation (P) compared to crude 178 
homogenate (H) protein from that sample. Blots were probed for PSD95, synaptophysin, 179 
histone and GAPDH. The level of the synaptic proteins varies between the preps, however 180 
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the enrichment of both synaptic proteins appears to be similar between preparations. B) Post-181 
mortem degradation was assessed by western blotting for NMDA NR2A subunit.  C) 182 
HUSPIR degradation index was calculated as the ratio of band 1 to band 2 and any cases 183 
falling below a ratio of 1 (black line) were excluded.  Total protein analysis was also used to 184 
determine whether any samples showed evidence of protein degradation. Boxes in panel (D) 185 
indicate the molecular weight ranges analysed for total protein stain. Quantification reveals 186 
no difference in total protein in BA41/42 (E) or BA17 (F) samples (One way ANOVAs, 187 
p>0.05).  188 
 189 
 190 
Fig. 2: Workflow. Samples were prepared from postmortem tissue and processed for 191 
proteomics analysis according to the workflow shown.   192 
 193 
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Following detection on the mass spec, quantitation of the dataset using MaxQuant 18and 194 
Andromeda search engine software 19 we identified 7148 protein identifications (IDs) in total. 195 
These 7148 identified proteins were then filtered to include only proteins identified by 2 or 196 
more unique peptides (Figure 3C).  This yielded 5678 proteins. A DAVID enrichment 197 
analysis of this filtered list of proteins served to further confirmed enrichment of the samples 198 
for synaptic material (Supplemental table 2). 199 
 200 
Supplemental table 2: DAVID Analysis confirms enrichment of synaptic proteins.  201 
 202 
Having confirmed that the proteomic data is likely to be representative of the synaptically 203 
enriched starting material we then filtered to include only those demonstrating differential 204 
abundance of equal to or greater twenty percent  (up or down regulated) in the comparison 205 
AD vs. ctrl in BA41/42 in APOE4 carriers (Fig. 3C). After applying these further two data 206 
filtering steps we obtained a set of 1532 protein IDs identified with high confidence and 207 
meeting our differential abundance criteria (Figure 3C).  208 
 209 
In-silico analysis revealed differences in abundance ratios correlating with increasing 210 
vulnerability for AD neuropathology 211 
To determine potential differences in the synaptic proteomes of AD patients vs. control 212 
subjects dependent on APOE genotype and brain region, we focused on the protein 213 
abundance ratios as calculated by dividing values from AD patients by matched control 214 
subjects, subcategorised for APOE3/4 or APOE3/3 genotype, and segregated by brain region 215 
(Fig. 3A-C).  More proteins were changed in AD patients compared to controls in BA41/42 216 
of APOE4 carriers than any other condition.  The numbers of protein changes increases 217 
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progressively from APOE3/3 BA17 < APOE3/3 BA41/42 < APOE3/4 BA17 < APOE3/4 218 
BA41/42.  Looking at the 15 most upregulated and downregulated pathways detected by 219 
Ingenuity Pathway Analysis software (Fig. 3D) reveals that several pathways involved in 220 
intracellular signalling, glial proteins involved in glia-neuron interactions, and the immune 221 
response are upregulated in AD compared to control with generally larger effects in the 222 
temporal cortex BA41/42.  Sirtuin signalling is the most upregulated pathway in AD vs 223 
control with higher levels in BA41/42 and in APOE4 carriers. Sirtuin 2 is increased 17% and 224 
sitruin 3 by 28% and Bax and CPS1, which are involved in sirtuin signaling in mitochondria 225 
are increased 28% and 43% respectively in AD APOE3/4 BA/41/42 compared to controls.  226 
Downregulated pathways include many involved in synaptic function such as synaptic long 227 
term potentiation, glutamate signalling, and calcium signalling. The most downregulated 228 
pathway in AD APOE3/4 BA/41/42  was oxidative phosphorylation including significant 229 
downregulation of proteins in complex I, IV, and V.  This pathway was  increased in BA17 230 
indicating a potential compensatory effect in BA17 which has less pathology at end stages of 231 
disease.  This combination of region specific decreases in synaptic and mitochondrial 232 
proteins is very interesting in light of our recent paper showing decreased numbers of 233 
mitochondria in synaptic terminals in BA41/42 using electron microscopy 20.   All pathways 234 
detected with IPA analysis are available in supplemental table 3. 235 
 236 
Our previous work examining synapses in human post-mortem tissue has revealed that the 237 
handling of the body and the tissue is critical for maintaining structural and molecular 238 
integrity of synapses 20, 21.  In particular, we observe that rapid cooling of the body after death 239 
preserves synapse structure and molecular integrity better even than short post-mortem 240 
intervals.  Therefore in this study we used samples only from the Edinburgh MRC Sudden 241 
Death Brain Bank whose robust handling protocol is carried out on each individual ensuring 242 
that the data is as comparable as possible.  This precluded precise age and sex matching of 243 
our control groups with APOE3/3 and APOE3/4 genotypes (see table 1), which could mean 244 
that there are confounding effects of age and sex on our AD/control comparisons.  However, 245 
when we compare BA41/42 of the AD APOE3/4 to AD APOE3/3 cases, which are 246 
reasonably age and sex matched, we observe many of the same pathways increased in AD 247 
APOE4 carriers compared to AD APOE3 carriers as those we observed in the comparison of 248 
AD vs control APOE4 carriers (Fig. 4D). Less changes were observed in BA17 from AD 249 
APOE4 carriers compared to AD APOE3 carriers. This strongly supports our conclusion that 250 
APOE4 influences the synaptic proteome in AD in a region-specific manner. Interestingly, in 251 
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non-demented controls when APOE4 carriers are compared to APOE3 carriers in BA41/42, 252 
there are changes in the opposite direction to those that are observed in E4 AD vs control. 253 
 254 
 255 
Fig. 3: Synaptic proteomes are altered by AD and APOE genotype A) Heat map with 256 
hierarchical clustering demonstrates the differential abundance of the 5678 individual 257 
proteins across “spared” and “vulnerable” brain regions and with APOE genotype. The ratios 258 
compare AD to control in each condition. B) Stacked bar chart demonstrates there is a direct 259 
correlation between the number of proteins that are differentially expressed, by 20% or more 260 
(up or down regulation), with the “vulnerability status’ of the synapses as determined by both 261 
genotype and brain region. C) Graphical representation of protein abundance ratios in the 262 
comparison AD vs. ctrl (APOE3/4, BA41/42) before (left) and after applying the filters of at 263 
least 2 unique peptide IDs and >20% change between AD and control (right). The dotted 264 
lines indicate a change of 20% up or down (note 4 proteins out of 5678 which have 265 
abundance ratios higher than 5 are excluded from the graph in panel C). D) Using Ingenuity 266 
Pathway analysis to investigate pathway alterations in the 1532 proteins that were changed 267 
more than 20% in the most vulnerable brain condition (APOE3/4 BA41/42) shows that in AD 268 
there is a clear upregulation of pathways involved in the immune response and cellular 269 
signaling and down regulation of several pathways involved in synaptic function including 270 
long term potentiation, glutamate signaling, and calcium ignaling.  These pathways were 271 
differentially regulated in the different brain regions and APOE genotypes. Comparing 272 
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APOE4 to APOE3 carriers within the control (con) and AD groups similarly reveals region-273 
specific effects of APOE isoform on the synaptic proteome.   Z-scores are plotted in D with 274 
upregulated proteins shown in red and downregulated in green. 275 
 276 
 277 
To further examine trends in protein changes in an unbiased manner, we performed clustering 278 
analysis to detect differences in the abundance ratios across these differentially vulnerable 279 
synaptic populations. Proteins were clustered according to their abundance profile across the 280 
four calculated ratios (Fig. 4). Each sphere represents an individual protein ID and the 281 
distances between the spheres indicate the similarity in abundance profile. Different colours 282 
are used to group proteins together in clusters based on abundance profile similarity. In order 283 
to analyse the impact/influence of APOE genotype and cortical region, we focused 284 
specifically on clusters showing a steady increase or decrease in protein abundance across the 285 
four groups or only demonstrating differences in protein abundance in APOE- ε3/4 carriers in 286 
BA41/42 (Fig. 4). In order to determine if these abundance profile specific clusters were 287 
associated with specific pathways and/or canonical cascades, we have carried out a higher 288 
order functional clustering analysis using IPA software. IPA pathway analysis and DAVID 289 
enrichment analysis highlighted multiple affected pathways.  In clusters 4, 5, 8 and 21 which 290 
have progressive decreases in AD/control ratios as pathological severity increases (Fig 4), we 291 
observe pathways involved in synaptic function are decreased including glutamate signalling, 292 
synaptic long term potentiation, GABA receptor signalling, CREB signalling, and synaptic 293 
long-term depression. Cluster 6 containing proteins that were sharply decreased in the 294 
condition with most pathology, AD APOE4 BA41/42, similarly showed decreases in 295 
pathways involved in synaptic function including CREB signalling and GABA receptor 296 
signalling, along with decreases in pathways implicated in mitochondrial function including 297 
oxidative phosphorylation (Fig 4).  298 
 299 
 300 
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 301 
Fig. 4: Clusters of protein changes. (A) Graphia Professional representation of proteomic 302 
abundance data across differentially vulnerable synaptic populations. Each sphere represents 303 
a single protein and the edge represents how similar their abundance trend is towards the 304 
other proteins in the dataset. The closer the spheres are the more similar the abundance trend. 305 
The colours represent the different clusters formed by grouping proteins with similar 306 
abundance trends. The resulting profiles were grouped into four different categories as shown 307 
in the example graphical abundance trends for further analysis. The annotation associated 308 
with each graph represents the cluster numbers which fit each trend and the number of 309 
associated proteins. Graphs B-E show the top pathway changes in the clusters indicated. 310 
 311 
 312 
Interestingly, when examining clusters 7, 9, and 18 which were progressively increased with 313 
pathological vulnerability, we observe proteins involved in autophagy and chemokine 314 
signalling were progressively upregulated in conditions of higher synaptic vulnerability (Fig 315 
4,). Clusters 1 and 2, which included proteins highly upregulated in AD APOE4 BA41/42 316 
compared to the other groups indicate increases in pathways involved in actin cytoskeleton 317 
signalling, NRF2 mediated oxidative stress response, PDGF signalling, and insulin receptor 318 
signalling, which all implicate non-neuronal contributors to synapse degeneration as has been 319 
recently emphasised for AD risk by genetic studies 22.  320 
 321 
Along with the unbiased bioinformatic analyses, we further interrogated our proteomics 322 
dataset to examine proteins of interest based on what is known about synapse degeneration in 323 
AD from model systems.  In addition to loss of proteins involved in synaptic function in 324 
remaining synapses in AD as shown with bioinformatics, it is likely that there is some degree 325 
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of synaptic remodelling/compensation taking place as some synaptic proteins were increased.  326 
The synaptic receptor TMEM97 is increased 2.8 fold in remaining synapses in AD vs control 327 
APOE4 carriers in BA41/42 (Fig 5).  This is particularly interesting because TMEM97 is the 328 
sigma 2 receptor, and compounds that disrupt interaction of Aβ and sigma 2 receptors are 329 
protective in mouse models and are being tested for efficacy in human AD as a therapeutic 23.  330 
 331 
Recent data strongly implicate the complement cascade and microglia in Aβ mediated 332 
synapse loss in mouse models of amyloid deposition 24, 25. Two studies recently demonstrated 333 
upregulation of components of the complement system in AD brain and influence of 334 
complement cascade in synapse dysfunction and loss in a mouse model of tauopathy 26, 27.    335 
Based on these data, we interrogated our human synaptoneurosome dataset to look at proteins 336 
important for microglial synapse phagocytosis and specifically the complement system.  337 
Pathway analysis reveals increases in CD40, IL-6, IL-8, IL-1, IL-2, IL-7 and acute phase 338 
response  signalling, indicating neuroimmune signalling between neurons and glia in 339 
synapses, which is modulated by APOE genotype (Fig 3,4, supplemental figure 3).  Further 340 
interrogation of the proteomics dataset shows increases in C1qA, B, and C in AD brain, 341 
which are most pronounced in BA41/42 of APOE3 carriers (over 2 fold increases).  We also 342 
detect complement components C1 and C4 which are increased in most conditions AD brain 343 
without a clear effect of APOE genotype (supplemental table 4).  344 
Log2 
Normalised 
Ratio AD/Ctrl 
3/3 41/42 
Log2 
Normalised 
Ratio AD/Ctrl 
3/4 41/42 
Log2 
Normalised 
Ratio AD/Ctrl 
3/3 17 
Log 
Normalised 
Ratio AD/Ctrl 
3/4 17 
Complement C1q subcomponent subunit A 1.77959139 0.69430641 1.0980274 0.93909556 
Complement C1q subcomponent subunit B 1.44369348 0.68392297 0.7091574 0.91265319 
Complement C1q subcomponent subunit C 1.0778657 0.60047611 0.46366574 0.73646894 
Complement C4-A 0.84763652 0.73464438 0.89934544 0.66442196 
Complement C4-B  0.81062454 0.98633814 -0.0877303 0.38715829 
Complement C1s 0.68375909 0.2130724 0.39700963 0.56568522 
Complement component 1 0.29882572 0.59348713 -0.5659684 0.40746573 
Supplemental table 4: Evidence for alterations in proteins involved in the complement 345 
cascade in human AD synapses. 346 
 347 
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In order to validate the proteomics data, we selected a subset of proteins for western blot 348 
analysis in BA41/42 whose levels should be increased or decreased just past our magnitude 349 
of change cutoff as this will be more indicative of the sensitivity of the MS than highly up or 350 
downregulated proteins.  We also selected a protein whose levels was unchanged to use as an 351 
internal control  (Fig 5, full blots shown in supplementary figure 3).28  352 
 353 
 354 
 355 
 356 
Figure 5:  Western blot validation of proteomic analysis. Quantitative fluorescent western 357 
blotting was used in BA41/42 of APOE4 cases to confirm changes in proteins seen with 358 
proteomics. Western blot validation from non-demented control (white bars) and AD cases 359 
(grey bars) show examples of proteins that were decreased unchanged, and increased in AD.  360 
Data are shown as mean and error bars represent the standard error of the mean. Each dot 361 
represents the value from a single case. Housekeeping proteins actin (A) and tubulin (B),  362 
commonly used loading controls, are downregulated in AD patients. C, D. Pre synaptic 363 
proteins (SNAP25) and post-synaptic (PSD95) respectively are downregulated in the 364 
synapses of AD patients. E.  Abundance of alpha synuclein, a presynaptic protein that is 365 
often associated with neurodegeneration, is also appreciably decreased in AD patients.  F. 366 
Mitochondrial protein SOD2 is unchanged in AD vs control. G. Annexin V is upregulated in 367 
the synapses of AD patients. H. TMEM97, a proposed synaptic receptor for Abeta is 368 
increased in AD. Total protein stained gels were used as a loading control as described in 29.  369 
Data are shown as means and standard errors with each dot representing an individual case.  370 
Non-cropped blots are found in supplementary figure 3. 371 
 372 
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 373 
 374 
Supplementary figure 3: Validation western blots (uncropped) of AD vs non demented 375 
control (NDC) from BA41/42 of people with APOE3/4 genotype.  Full blots are shown for 376 
actin and SNAP25 (A), PSD95 and alpha-synuclein (B), SOD2 (C), annexin V (D), 377 
TMEM97 (E), beta tubulin (F), and total protein at high intensity (G) and low intensity (H). 378 
Each of the molecular weight ranges in H were quantified for each lane, shown in (I). 379 
Comparisons between proteomics and western blot data are shown in J. 380 
 381 
Discussion 382 
 383 
Of the pathological changes associated with dementia, the best correlate to the extent of 384 
memory decline in life is the loss of synapses. Synapses are exquisitely complicated 385 
structures requiring thousands of proteins for the complex process of establishing, 386 
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maintaining, and undergoing synaptic transmission. Work from animal models and human 387 
post mortem tissue indicates that synapse degeneration is a driving force in disease 388 
progression in AD. However, to date there has been a lack of data on the precise molecular 389 
changes in synapses in human AD brain, which impedes the design of hypothesis driven 390 
experiments to understand mechanisms of synapse degeneration in animal models that are 391 
likely to be relevant to human disease.  In the literature, we found 19 publications using 392 
proteomics on human AD brain tissue (supplemental table 1). In proteomics studies 393 
examining whole tissue homogenates from AD brains without considering APOE genotype, 394 
there have been quite varied results.  Three studies show decreases in synaptic proteins or 395 
pathways involved in synaptic function, which could have been explained by synapse loss 30, 396 
31, 32.  To our knowledge only one previous study examined the effects of APOE on synaptic 397 
proteins 33. This study used whole tissue homogenates from AD and control subjects for 398 
proteomics but focused their analysis on a group of 191 proteins that had previously been 399 
detected in synaptosome fractions of healthy subjects.  With this method, they observed a 400 
downregulation of glutamate signalling proteins and an effect of APOE4 genotype on the 401 
abundance of these synaptic proteins.  Our results significantly expand upon these findings as 402 
we biochemically isolated synaptoneurosomes from AD and control subjects and detected 403 
over 5,500 proteins, which is over 25 times more proteins examined than in the previous 404 
study of synaptic proteins.  Synaptoneurosome preparations have not previously been used in 405 
proteomic studies of AD. Synaptoneurosomes, unlike other synaptic fractions, contain both 406 
the presynaptic and postsynaptic compartments, which is important due to data from model 407 
systems implicating both pre and post synapses in degenerative mechanisms. Further, the 408 
preparation might retain parts of glial processes closely associated with the synapse, which is 409 
key for understanding the role of non-neuronal cells in synapse degeneration, an important 410 
topic in the field 22.  411 
  412 
We observed that multiple pathways including those associated with synaptic and 413 
mitochondrial function were downregulated with increasing vulnerability and other pathways 414 
including intracellular signalling and neuroimmune signalling proteins were increased with 415 
increasing vulnerability. This is encouraging as dysfunctional synaptic signalling is consistent 416 
with multiple lines of evidence from AD animal models8, 34, 35. Some of the proteins that we 417 
observe are reduced in AD synapses have been observed as CSF biomarkers associating with 418 
disease.  For example, we observe a 25% decrease in neurexin 2 and over 30% decrease in 419 
neurogranin abundance in  AD APOE4 superior temporal gyrus compared to controls, 420 
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whereas  recently published biomarker studies observed increases in neurexin 2 and 421 
neurogranin in CSF of people with mild cognitive impairment or AD 36, 37, 38.    In another 422 
study of CSF, a group of 9 synaptic proteins (GluR2, GluR4, Neuroligin-2, Neurexin-3A, 423 
Neurexin-2A, Calsynytenin-1, Syntaxin-1B, Thy-1, and VAMP-2)  were increased before 424 
markers of neurodegeneration are observed  39.  Not only does this CSF data serve to further 425 
highlight the veracity of the proteomic data generated here, but critically, it also supports the 426 
notion that proteins may be removed from synapses and at least some of these cleared from 427 
the brain via CSF. 428 
 429 
In addition to the synaptic signalling pathway changes, we observe interesting changes in 430 
immune-related signals in AD synapses. In recent work examining both iPSCs and human 431 
brain tissue, APOE4 was strongly associated with reduced expression of regulators of 432 
synaptic function and increased expression of microglial genes associated with the immune 433 
response 40.  APOE has been shown to interact with and modulate the immune and 434 
inflammatory system in the brain especially through its interaction with another important 435 
AD genetic risk factor TREM2 41. Our study also found that proteins involved in the immune 436 
system and neuroimmune signalling are dysregulated in the AD synapse. Recent evidence has 437 
indicated that the complement system of innate immunity, particularly complement 438 
components C1q and C3, are involved in synaptic death in mouse models both downstream 439 
of Aβ and tau pathology, and that ApoE forms a complex with activated C1q which blocks 440 
initiation of the complement cascade 24, 25, 26, 27, 42. Our study highlights the importance of 441 
these pathways in human AD brain and shows that other proteins in this cascade including 442 
complement component C4, HLA-1, and Clusterin are all increased at the synapse in AD 443 
presenting innate immunity as an attractive area for further study and therapeutic 444 
intervention. Our data indicate that within remaining synapses in human AD brain, APOE4 is 445 
associated with altered levels of proteins involved in synaptic function and proteins involved 446 
in the innate immune system. One possible interpretation of these data supports the 447 
hypothesis that microglia are involved in synaptic pruning during disease. 448 
 449 
Synapses have high energy demands requiring local mitochondrial ATP production.  Both Aβ 450 
and tau have been observed in model systems to impact mitochondrial function and the 451 
intracellular transport of mitochondria, which impair synaptic function 43, 44, 45. And there is 452 
some evidence that APOE4 can impair mitochondria function in cell culture .46 However, the 453 
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role of APOE4 in synaptic mitochondrial function in human brain has not been studied.  We 454 
observe region and APOE specific changes in proteins involved oxidative phosphorylation 455 
with a strong decrease in BA41/42 of AD patients that was larger in APOE4 carriers than 456 
APOE3 carriers.  Conversely, this pathway was  increased in BA17 with the strongest 457 
increase in E3 carriers.  This could reflect a compensatory increase  in mitochondrial function 458 
in brain regions that are very early in the disease process. Consistent with the BA41/42 data, 459 
we recently observed a decrease in presynaptic terminals containing multiple mitochondria in 460 
the temporal cortex of AD patients 20. 461 
 462 
Synaptic degeneration is an important part of AD pathogenesis. Further understanding this 463 
process and how to delay and/or halt it may lead us towards important novel therapeutic 464 
targets not only for AD but also for other diseases for which synapse loss is an integral or 465 
important process. By coupling subcellular fractionation with anatomical knowledge of 466 
regional vulnerability and human patient genetics we were able to generate the most 467 
comprehensive synaptic proteomics profiling datasets from human AD patient samples to 468 
date. Importantly, we have determined its accuracy through experimental validation and links 469 
to existing published literature on mechanisms and biomarker identification. As an example 470 
of the potential utility of such data we were able to begin to uncover how AD and APOE4 471 
impact synaptic composition and may be leading to synaptic degeneration. Although in this 472 
discussion we have highlighted specific proteins and cascades correlating with regional 473 
vulnerability and discussed their potential roles in disease progression and /or regulation this 474 
was done to highlight the potential utility of our dataset. There are many other potentially 475 
important proteins and pathways in these data to explore in future stidies. We have made the 476 
data freely available and hope that this will provide a useful resource for other researchers in 477 
the field to use at their discretion. The results described here demonstrate that APOE 478 
genotype has a profound impact on the molecular fingerprint of the synapse and that further 479 
understanding of the effects of these protein changes may contribute to our understanding of, 480 
and ultimately the development of novel therapies for AD.   481 
 482 
Methods 483 
Subjects 484 
Use of human tissue for post-mortem studies has been reviewed and approved by the 485 
Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics 486 
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committee, AMREC (ACCORD is the Academic and Clinical Central Office for Research 487 
and Development, a joint office of the University of Edinburgh and NHS Lothian, approval 488 
number 15-HV-016). The Edinburgh Brain Bank is a Medical Research Council funded 489 
facility with research ethics committee (REC) approval (11/ES/0022).   490 
 491 
Fresh frozen brain tissue for proteomics and paraffin embedded tissue for examination of 492 
pathology was provided from superior temporal gyrus (BA41/42) and primary visual cortex 493 
(BA17). Tissue was requested from clinically diagnosed AD and control subjects.  All cases 494 
were examined by a neuropathologist, and after the proteomics results were returned, it was 495 
noted that one of the AD cases was neuropathologically classified as frotntotemporal 496 
dementia with tau-associated corticobasal degeneration (table 1).     497 
 498 
APOE genotyping 499 
DNA was extracted from ~25mg of cerebellum for each case using the QIAamp DNA mini 500 
kit (Qiagen, Hilden, Germany), which was used as per the manufacturer’s instructions. 501 
Polymerase chain reaction (PCR) was performed on the extracted DNA.  10μl of 2x Master 502 
mix (Promega, Madison, WI) was combined with 1μl of primer stock (20μM forward primer, 503 
20μM reverse primer), 2μl of DMSO (Sigma-Aldrich, St Louis, MO), 6μl ddH2O and 1μl of 504 
isolated DNA. The forward primer was 5’taagcttggcacggctgtccaagg3’ and the reverse primer 505 
5’acagaattcgccccggcctggtacactgcc3’ (Figure 2.2A). APOE ε2, APOE ε3, and APOE ε4 506 
plasmids (generously donated by Dr E Hudry) were also amplified by PCR to use at as 507 
reference and were treated in the same way as unknown samples throughout.  PCR product 508 
was digested using the restriction endonuclease HhaI (New England Biolabs, Ipswich, MA). 509 
For this 0.5μl of enzyme, 2.5μl of 10x CutSmart buffer (New England Biolabs, Ipswich, MA) 510 
and 2μl of ddH2O were added to each PCR reaction tube to give a total volume of 25μl. The 511 
final volume contains 50 mM Potassium Acetate, 20 mM Tris-acetate, 10 mM Magnesium 512 
Acetate, and 100 μg/ml BSA as a result of the CutSmart buffer and 10 units of HhaI.  After 513 
digestion incubation 5μl of 6x Blue Loading dye (Promega, Madison, WI) containing 0.4% 514 
orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10mM Tris-515 
HCl (pH 7.5) and 50mM EDTA (pH 8.0) was added to the the reaction tube. 14μl of this 516 
mixture was then loaded onto precast 15 well Novex TBE 20% gel (Thermo Fisher Scientific, 517 
Waltham, MA) using a 25µL Hamilton Syringe. The DNA were then separated by size using 518 
electrophoresis for 2 hours at 200V. The gels were run in an XCell SureLock™ Mini-Cell 519 
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(Invitrogen, Carlsbad, CA) using Novex TBE running buffer (Thermo Fisher Scientific, 520 
Waltham, MA). Bands were stained with either 2μg/ml ethidium bromide (Sigma-Aldrich, St 521 
Louis, MO) or SYBR safe DNA Gel Stain (Thermo Fisher Scientific, Waltham, MA) and 522 
visualized with an ultraviolet gel imaging system (Syngene, Cambridge, UK). 523 
 524 
Amyloid beta and Tau staining in human cortical sections 525 
Tissue sections were stained for amyloid beta and tau according to a previous study 47. 526 
Briefly, fresh post-mortem tissue blocks were fixed in formalin and dehydrated in an 527 
ascending alcohol series. Three paraffin waxing stages were performed and 4μm thick tissue 528 
sections were cut on a Leica microtome and collected on glass slides. Immunohistochemistry 529 
for amyloid beta (BA4, M087201-2, Dako) and pTau (AT8, MN1020, Thermo) was 530 
performed using the Novolink Polymer detection system and visualized using DAB as 531 
chromogen. Images were acquired using an upright Zeiss axioImager equipped with 532 
MicroBrightfield stereology software. 533 
 534 
Synaptoneurosome preparation 535 
Brain homogenates and synaptic fractions were prepared as described in Tai et al. 2012 48. In 536 
brief, ~300mg of cortical tissue was homogenized on ice in homogenization buffer (25 mM 537 
HEPES pH 7.5, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, protease inhibitors 538 
(roche complete mini), phosphatase inhibitors (Millipore, 524629)). The homogenate was 539 
filtered through 2 layers of 80μm nylon filter (Millipore, NY8002500) and saved as crude 540 
homogenate. The crude homogenate was further filtered through a 5 μm filter (Millipore, 541 
SLSV025NB) and centrifuged at 1000g for 5 min. The pellet was washed once, then the 542 
supernatant was removed and the pellet was resuspended in in label-free buffer [100 mM 543 
Tris-HCl (pH7.6) 4% (w/v) SDS] containing 1% protease cocktail inhibitor (Thermo Fisher, 544 
UK). Homogenates were centrifuged at 20,000 x g for 20 minutes at 4°C with the soluble 545 
fraction of each sample transferred to Lo-Bind tubes (Sigma Aldrich). Protein determination 546 
using the Bicinchoninic acid assay (Pierce, UK) was carried out according to manufacturer’s 547 
guidelines. 548 
 549 
SDS-PAGE and western blotting 550 
SDS-PAGE and western blotting were performed as described previously 49. Briefly, 5μg of 551 
protein from synaptoneurosome fractions and molecular weight marker (Li-Cor, Cambridge, 552 
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UK) was loaded onto NuPAGE 4-12% Bis-Tris precast polyacrylamide 15 well gels 553 
(Invitrogen, Paisley, UK). Proteins were transferred to polyvinylidene fluoride (PDVF) 554 
membranes and blocked using Odyssey Blocking buffer (927-40,000, Li-Cor) diluted 1:1 in 555 
PBS. Primary antibodies were incubated overnight in blocking buffer and proteins were 556 
detected on an Odyssey system using 680 and 800 IR dye secondary antibodies diluted 557 
1:10000 in blocking buffer (table 2 shows antibodies used in western blots). Total protein 558 
stains were performed with Instant Blue total protein stain per manufacturer instructions 559 
(Expedeon). 560 
 561 
LC-MS/MS analysis 562 
Pools containing equal amounts of protein (25 μg per case) were prepared of each of the 8 563 
groups (control APOE3/3 BA41/42, control APOE3/3 BA17, control APOEx/4 BA41/42, 564 
control APOEx/4 BA17, AD APOE3/3 BA41/42, AD APOE3/3 BA17, AD APOEx/4 565 
BA41/42, AD APOEx/4 BA17).  Preparation of the samples, quantification, and 566 
bioinformatics was carried out according to standardized protocols 12, 13, 14.  567 
 568 
Samples were lysed in 4%SDS + 100mM tris prior to protein estimation by microBCA. Each 569 
sample was then reduced with 100 mM DTT and samples then processed using the FASP 570 
protocol 50 with some modifications. Samples were initially diluted 1:10 into 8M Urea and 571 
buffer exchanged to remove the SDS and tris buffer, filters were then washed 3 times with 572 
100 mM Tris-HCL pH 8 then another 3 times with 100 mM triethyl ammonium bicarbonate 573 
(TEAB). Proteins on the filters are then digested twice at 30oc with trypsin (2 x 1ug), first 574 
overnight and then for another 6h in a final volume of 200 µl prior to addition of 200ul of 575 
500mM NaCl. Samples were then desalted using a SPE cartridge (Empore-C18, Agilent 576 
Technologies, 7mm/3ml) and the peptides dried in a speedvac (Savant). 577 
  578 
Desalted tryptic peptides (25µg each sample) were then dissolved in 100 µl 100 mM TEAB. 579 
The different 8 TMT labels were dissolved in 41µL of anhydrous acetonitrile, and each label 580 
then added to a different sample. The mixtures were incubated for 1 hour at room 581 
temperature and the labelling reaction was then quenched by adding 8µL of 5% 582 
hydroxylamine. Following labelling with TMT, samples were mixed, desalted using a SPE 583 
cartridge (Empore-C18, Agilent Technologies, 7mm/3ml) and the peptides dried in a 584 
speedvac (Savant). Samples were then dissolved in 200 μL ammonium formate (10 mM, pH 585 
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10) and peptides fractionated using High pH RP HPLC.   A C18 Column from Waters 586 
(XBridge peptide BEH, 130Å, 3.5 µm 2.1 X 150 mm, Ireland) with a guard column 587 
(XBridge, C18, 3.5 µm, 2.1X10mm, Waters) are used  on a Ultimate 3000 HPLC (Thermo-588 
Scientific). Buffers A and B used for fractionation consists,  respectively of 10 mM 589 
ammonium formate in milliQ water and 10 mM ammonium formate with 90% acetonitrile, 590 
both buffers were adjusted to pH 10 with ammonia.  Fractions were collected using a WPS-591 
3000FC auto-sampler (Thermo-Scientific) at 1 min intervals. Column and guard column were 592 
equilibrated with 2% buffer B for 20 min at a constant flow rate of 0.2 ml/min. Samples (175 593 
µl) were loaded onto the column at 0.2 ml/min. Peptides were eluted from the column with a 594 
gradient of 2% buffer B to 5%B in 6 min then from 5% B to 60% B in 50 min. The column is 595 
washed for 16 min at 100% buffer B and equilibrated at 2% buffer B for 20 min as mentioned 596 
above.   The fraction collection started 1 min after injection and stopped after 80 min (total of 597 
80 fractions, 200 µl each). The total number of fractions concatenated was set to 20 by non-598 
contiguous pooling and the content of the fractions dried and resuspended in 50 µl of 1% 599 
formic acid prior to analysis by nLC-MS/MS. 600 
  601 
Analysis of peptides was performed using a Q-Exactive-HF (Thermo Scientific) mass 602 
spectrometer coupled with a UltiMate 3000 RSLCnano (Thermo Scientific) UHPLC system. 603 
nLC buffers were as follows:  buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q 604 
water (v/v)) and buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v). 605 
Aliquots of 15 μL of each sample (50ul in total) were loaded at 5 μL/min onto a trap column 606 
(100 μm × 2 cm, PepMap nanoViper C18 column, 5 μm, 100 Å, Thermo Scientific) 607 
equilibrated in 98% buffer A. The trap column was washed for 6 min at the same flow rate 608 
and then the trap column was switched in-line with a Thermo Scientific, resolving C18 609 
column (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). The peptides were 610 
eluted from the column at a constant flow rate of 300 nl/min with a linear gradient from 95% 611 
buffer A to 40% buffer B in 122 min, and then to 98% buffer B by 132 min. The column was 612 
then washed with 95% buffer B for 15 min and re-equilibrated in 98% buffer A for 32 min. 613 
Q-Exactive HF was used in data dependent mode. A scan cycle comprised MS1 scan (m/z 614 
range from 335-1800, with a maximum ion injection time of 50 ms, a resolution of 120 000 615 
and automatic gain control (AGC) value of 3x106) followed by 15 sequential dependant MS2 616 
scans (with an isolation window set to 0.7 Da, resolution at 60000, maximum ion injection 617 
time at 200 ms and AGC 1x105. To ensure mass accuracy, the mass spectrometer was 618 
calibrated on the first day that the runs are performed. 619 
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 620 
The raw mass spectrometric data files obtained for each experiment were collated into a 621 
single quantitated dataset using MaxQuant 1.6.0.16 18 and Andromeda search engine software 622 
19 with enzyme specificity set to trypsin. Other parameters used were: (i) variable 623 
modifications, deamidation (NQ), oxidation (M), protein N-acetylation, gln-pyro-glu; (ii) 624 
fixed modifications, carbamidomethylation (C); (iii) database: uniprot-human_Sept2017 625 
database; (iv) Reporter ion MS2 – TMT labels: TMT8plex_Nter and TMT 8plex-Lys ; (v) 626 
MS/MS tolerance: FTMS- 10ppm, ITMS- 0.02 Da; (vi) maximum peptide length, 6; (vii) 627 
maximum missed cleavages, 2; (viii) maximum of labelled amino acids, 3; and (ix) false 628 
discovery rate, 1%. Peptide ratios were calculated using ‘Reporter Intensity’ Data that was 629 
normalised using 1/median ratio value for each identified protein group per labelled sample. 630 
 631 
In silico analyses 632 
Filtered data was utilised for all bioinformatics statistical analyses and filtered by the 633 
following criteria: proteins identified by >1 peptide and that demonstrated a ±>20% change 634 
between APOEx/4 BA41/42 AD and control subjects.  The Database for Annotation 635 
Visualization and Integrated Discovery (DAVID) was used to test whether synaptic protein 636 
sets were enriched in the samples 51.  To obtain further insight into potential pathways 637 
changed in AD synapses, Ingenuity Pathway Analysis (IPA, Ingenuity Systems) was used as 638 
previously described 12, 13, 52 with the interaction data limited as follows: direct and indirect 639 
interactions; experimentally observed data only; 35 molecules per network; 10 networks per 640 
dataset. Prediction activation scores (z- scores) were calculated in IPA. Expression clustering 641 
was performed in Biolayout Express 3D software by applying Markov clustering algorithms 642 
to raw proteomic data (MCL 19 2.2) as previously described in 13. All graphs were clustered 643 
using Pearson correlation r=0.96. 644 
 645 
Data sharing 646 
Unfiltered proteomics data is included as supplemental table 5. The mass spectrometry 647 
proteomics data have also been deposited to the ProteomeXchange Consortium via the 648 
PRIDE partner repository 53, with the dataset identifier PXD013753.  DAVID analysis is 649 
provided in supplemental table 2. The full IPA analysis from Figure 3 is in supplemental 650 
table 3. Complement proteins identified are in supplemental table 4. Filtered proteomics data 651 
used for IPA analysis in figure 3 is provided in supplemental table 6.  652 
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